<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

by Targeted Oncology | July 31, 2023
placeholder

During a Targeted Oncology Case-Based Roundtable event, Brad Haverkos, associate professor of medicine at CU School of Medicine, and other participants discussed the choice of treatment options for a patient with relapsed/refractory diffuse large B-cell lymphoma who previously received R-CHOP and pola-BR.

Topics: Press Coverage